GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Additional Paid-In Capital

Novavax (MEX:NVAX) Additional Paid-In Capital : MXN92,325 Mil(As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Novavax Additional Paid-In Capital?


Novavax's quarterly additional paid-in capital increased from Sep. 2024 (MXN88,422 Mil) to Dec. 2024 (MXN93,880 Mil) but then stayed the same from Dec. 2024 (MXN93,880 Mil) to Mar. 2025 (MXN92,325 Mil).

Novavax's annual additional paid-in capital declined from Dec. 2022 (MXN72,876 Mil) to Dec. 2023 (MXN71,159 Mil) but then increased from Dec. 2023 (MXN71,159 Mil) to Dec. 2024 (MXN93,880 Mil).

Novavax Additional Paid-In Capital Historical Data

The historical data trend for Novavax's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Additional Paid-In Capital Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50,435.69 68,762.25 72,875.64 71,158.83 93,879.91

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69,783.52 82,032.81 88,421.85 93,879.91 92,324.77

Novavax Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Novavax Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Novavax's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Additional Paid-In Capital
Comparable Companies
OCUL INVA VRDN MNKD VERA AUPH MLYS LQDA DYN CLDX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NVAX:USA NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Website
https://www.novavax.com
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.